Elastography

Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis

Retrieved on: 
Mittwoch, Juni 5, 2024
Biotechnology, Hospitals, Health, Pharmaceutical, Clinical Trials, Biomarker, Inflammation, Cirrhosis, Liver disease, Itch, Associate, PPAR, Doctor of Philosophy, Quality of life, Food, Gilead Sciences, Alkaline phosphatase, Science, MD, NDA, TB, European Medicines Agency, Safety, Therapy, Female, UDCA, NRS, Elastography, Ursodeoxycholic acid, Month, Bachelor of Science, MHRA, Master of Science, Cholestasis, Interim, University of Birmingham, ULN, MBBS, Acquisition, FDA, University, Congress, MRCP, Liver injury, EMA, ALP, CP, EASL, PBC, Primary biliary cholangitis, Pharmaceutical industry

“The data presented at EASL further support the sustained efficacy and safety profile of seladelpar observed across its robust development program, including a capacity to normalize ALP values for many of the people studied with PBC.

Key Points: 
  • “The data presented at EASL further support the sustained efficacy and safety profile of seladelpar observed across its robust development program, including a capacity to normalize ALP values for many of the people studied with PBC.
  • Participants received 10 mg seladelpar, once daily, for up to 155 weeks in the current analysis of the ASSURE cohort.
  • “The long-term efficacy and safety interim results from ASSURE demonstrate that seladelpar may meaningfully raise the bar in PBC.
  • Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) have also accepted seladelpar for review.

Dr. Phillip Oberg Joins Utah Gastro in St. George

Retrieved on: 
Donnerstag, Mai 30, 2024
Patient, Valley Hospital, Health, Liver disease, Food, ERCP, Medicine, Utah Valley University, Elastography, EGD, Nutrient, Colonoscopy, Internal medicine

St. George, UT, May 30, 2024 (GLOBE NEWSWIRE) -- Utah Gastroenterology welcomes the addition of Dr. Phillip Oberg, a board certified professional who treats all gastrointestinal diseases, while specializing in performing EGD, colonoscopy, ERCP, video capsule endoscopy, fibroscan, and treating esophageal dysmobility and liver disease.

Key Points: 
  • St. George, UT, May 30, 2024 (GLOBE NEWSWIRE) -- Utah Gastroenterology welcomes the addition of Dr. Phillip Oberg, a board certified professional who treats all gastrointestinal diseases, while specializing in performing EGD, colonoscopy, ERCP, video capsule endoscopy, fibroscan, and treating esophageal dysmobility and liver disease.
  • Dr. Oberg is board certified in Internal Medicine, received his undergraduate degree from Utah Valley University, and his medical degree from Touro University Nevada College of Osteopathic Medicine.
  • I have always been interested in our organ systems that are able to take our food and provide nutrients in a dynamic functioning body,” says Dr. Oberg.
  • Utah Gastro is at 368 E. Riverside Dr., Suite A, St. George, UT , and is open Monday through Friday, 8am to 5pm.

ECHOSENS APPOINTS DR. VICTOR DE LÉDINGHEN AS CHIEF MEDICAL OFFICER

Retrieved on: 
Dienstag, März 26, 2024
Diagnosis, Health, Liver disease, Cornell University, Patient, Research, Elastography, BMS, MASH, MD, Pharmaceutical industry

PARIS, March 26, 2024 /PRNewswire/ -- Echosens announced today the appointment of Victor de Lédinghen, MD PhD, as the company's new Chief Medical Officer.

Key Points: 
  • PARIS, March 26, 2024 /PRNewswire/ -- Echosens announced today the appointment of Victor de Lédinghen, MD PhD, as the company's new Chief Medical Officer.
  • With over two decades of clinical experience, Dr. de Lédinghen brings unparalleled expertise to advance Echosens' mission of revolutionizing liver health diagnostics.
  • As one of the earliest adopters of Echosens' FibroScan® technology since 2003, Dr. de Lédinghen has steadfastly advocated for its pivotal role in patient management.
  • As Chief Medical Officer, Dr. de Lédinghen will lead Echosens' clinical evidence-generation efforts, represent the company in medical forums, foster physician and pharmaceutical partnerships, and contribute to product development.

ECHOSENS APPOINTS DR. VICTOR DE LÉDINGHEN AS CHIEF MEDICAL OFFICER

Retrieved on: 
Dienstag, März 26, 2024
Diagnosis, Health, Liver disease, Cornell University, Patient, Research, Elastography, BMS, MASH, MD, Pharmaceutical industry

PARIS, March 26, 2024 /PRNewswire/ -- Echosens announced today the appointment of Victor de Lédinghen, MD PhD, as the company's new Chief Medical Officer.

Key Points: 
  • PARIS, March 26, 2024 /PRNewswire/ -- Echosens announced today the appointment of Victor de Lédinghen, MD PhD, as the company's new Chief Medical Officer.
  • With over two decades of clinical experience, Dr. de Lédinghen brings unparalleled expertise to advance Echosens' mission of revolutionizing liver health diagnostics.
  • As one of the earliest adopters of Echosens' FibroScan® technology since 2003, Dr. de Lédinghen has steadfastly advocated for its pivotal role in patient management.
  • As Chief Medical Officer, Dr. de Lédinghen will lead Echosens' clinical evidence-generation efforts, represent the company in medical forums, foster physician and pharmaceutical partnerships, and contribute to product development.

Echosens Raises the Standard for Liver Disease Assessment with Next Generation FibroScan®

Retrieved on: 
Montag, Februar 26, 2024
Liver, Anxiety, Liver disease, Physician, Obesity, MAFLD, Growth, Learning curve, Health care, Hepatology, MASH, Elastography, Gold, Health, Automation, Patient, Diagnosis, Workflow, Medical imaging

WALTHAM, Mass., Feb. 26, 2024 /PRNewswire/ -- More than 100 million people in the U.S. are affected by some form of liver disease, but only 4.5 million adults have been diagnosed with the condition. Responding to the dire need for enhanced liver health management, Echosens, the leader in liver health, introduces its new Guided Vibration-Controlled Transient Elastography (VCTE)™ technology, available only on new FibroScan® systems. An essential tool in the battle against liver disease, this next-gen FibroScan launch meets the urgent need for precise, efficient, and non-invasive liver assessment, delivering on the needs of healthcare professionals at the forefront of patient care.

Key Points: 
  • An essential tool in the battle against liver disease, this next-gen FibroScan launch meets the urgent need for precise, efficient, and non-invasive liver assessment, delivering on the needs of healthcare professionals at the forefront of patient care.
  • This innovation elevates liver care standards, assuring top-tier disease assessment for all patients, including obese patients, where assessments were previously limited."
  • As the global leader in liver health, Echosens is committed to empowering healthcare professionals with the gold standard non-invasive solution for the comprehensive management of liver health.
  • This evolution signifies a leap forward in simplifying diagnosis and disease management – making liver assessments more accessible and seamlessly integrated in practices than ever before.

Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference

Retrieved on: 
Donnerstag, Januar 4, 2024
Database, Conference, Elastography, Risk, Registry, NASH, Biopsy, Fatty liver disease, Research, Disease, Health, Cirrhosis, Abstract, MASH, FAST, Patient, Therapy, Fibrosis, Medical imaging

Jesse Fishman, Senior Director, Health Economics and Outcomes Research at Madrigal, stated, “We are gaining important new insights about the serious risks and complications associated with uncontrolled NASH through analyses of real-world data from patient registries and health system databases.

Key Points: 
  • Jesse Fishman, Senior Director, Health Economics and Outcomes Research at Madrigal, stated, “We are gaining important new insights about the serious risks and complications associated with uncontrolled NASH through analyses of real-world data from patient registries and health system databases.
  • The serious burden of uncontrolled NASH on patients and the health system is coming into focus: as the disease progresses to cirrhosis, patients face markedly elevated risk of liver-related and cardiovascular outcomes.
  • Among patients with cirrhosis, ≥25% were not seen by a specialist at the recommended frequency of once per year.
  • This finding underscores the necessity of revisiting current cardiovascular risk models for patients with NASH to incorporate more holistic and liver-specific variables.

FibroScan® by Echosens Recognized in AASLD Practice Guidance on Managing Portal Hypertension and Varices in Cirrhosis

Retrieved on: 
Freitag, November 10, 2023
Elastography, Lipinski's rule of five, Dominique, Literature, AASLD, HVPG, Cirrhosis, Liver disease, Mortality, Patient, SSM, Varices, Prognosis, Diagnosis, Decompensation, Chronic liver disease, Platelet, Medical imaging

PARIS and WESTBOROUGH, Mass., Nov. 10, 2023 /PRNewswire/ -- The American Association for the Study of Liver Disease (AASLD) has released new guidance advocating noninvasive tests like FibroScan® for the management of advanced liver disease, including assessment of clinically significant portal hypertension and varices in cirrhosis. This evidence-based approach could impact health outcomes for the majority of asymptomatic patients with this condition.

Key Points: 
  • "Managing portal hypertension in cirrhotic patients is a daily challenge for healthcare professionals," said Jon Gingrich, CEO of Echosens North America .
  • "Given the high mortality rates associated with these conditions, there's an urgent need for effective treatments and early diagnosis.
  • The latest guidance underscores the promise of noninvasive methods for monitoring advanced liver disease patients."
  • This new guidance encapsulates optimal practices for identifying and managing portal hypertension and varices in chronic liver disease.

Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances

Retrieved on: 
Donnerstag, Oktober 5, 2023
Cardiology, Data Management, Technology, FDA, Other Health, Diabetes, Health, Health Technology, Apps, Applications, Software, Clinical Trials, Cognitive behavioral therapy, Biomarker, Diet, Hypertension, Obesity, Translation, Public, Prevalence, AGA, T2D, MD, Liver disease, Therapy, Smartphone, Safety, NASH, Principal, Senior counsel, PDT, Elastography, American Gastroenterological Association, NAFLD, ALT, CBT, Hyperlipidemia, MASH, Enzyme, Patient, Quality of life, Dietary supplement, Pharmaceutical industry, Medical imaging

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced the pre-print publication of the LivVita study's results in Gastro Hep Advances, a peer reviewed journal produced by the American Gastroenterological Association (AGA).

Key Points: 
  • Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced the pre-print publication of the LivVita study's results in Gastro Hep Advances, a peer reviewed journal produced by the American Gastroenterological Association (AGA).
  • The study successfully met its primary endpoint by reducing liver fat within 90 days, while also achieving key secondary endpoints related to improved liver health without any device related adverse events.
  • The LivVita study evaluated Better Therapeutics’ novel CBT platform that targets individuals’ thoughts and beliefs related to improving healthy behaviors, such as diet and physical activity.
  • Better Therapeutics' novel CBT platform has already demonstrated clinically meaningful outcomes in type 2 diabetes (T2D), hypertension, and hyperlipidemia.

An Unforgettable Evening at Westmount Public Library Draws Rave Reviews

Retrieved on: 
Freitag, September 22, 2023
Knowledge, Canada, Liver disease, Obesity, NASH, Diabetes, Culture, Liver, Human, Fatty liver disease, Language, Metabolism, Medicine, Westmount Public Library, Non-alcoholic fatty liver disease, Diagnosis, NAFLD, Health, Empowerment, Dietary supplement, Hepatology, Elastography

TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- On the evening of September 19, 2023, the Fatty Liver Alliance, a Canadian not-for-profit charity, hosted, at the Westmount Public Library, in Westmount, Quebec, an extraordinary event that saw an overwhelming turnout of 50 community members.

Key Points: 
  • TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- On the evening of September 19, 2023, the Fatty Liver Alliance, a Canadian not-for-profit charity, hosted, at the Westmount Public Library, in Westmount, Quebec, an extraordinary event that saw an overwhelming turnout of 50 community members.
  • This Café Scientifique community education event is a unique opportunity for an in-depth understanding of liver disease, diabetes, and metabolic health.
  • The evening was a blend of information, interaction, and insight, as evidenced by one attendee's remark: "This event exceeded all expectations.
  • The importance of the topic, notably fatty liver, was underscored by numerous participants, with many calling for greater public awareness.

Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

Retrieved on: 
Montag, Mai 22, 2023
COPD, Elastography, Pancreatitis, NASH, Diabetes, COVID-19, Biomarker, Doctor of Philosophy, Șaeș, Dicarboxylic acid, SAE, MD, Liver, Patient, Risk, Colorado EKG Repository, ALT, Entrepreneurship, FDA, Headache, AST, Safety, Disease, Pharmaceutical industry, Medical imaging

EDISON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence (“AI”)-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced positive topline results from its recently completed Phase 2 ALTITUDE-NASH clinical trial.

Key Points: 
  • Other safety labs, EKGs, and physical exams did not reveal any safety signals or concerns over the course of the study.
  • This trial also serves as a bridge to Hepion’s current 12-month Phase 2b ASCEND-NASH liver biopsy-based trial.
  • The test is minimally invasive and is able to sensitively track changes in the degree of liver function impairment.
  • This contrasts with liver biopsy results, which are obtained through a more invasive procedure and only documents liver pathology, not liver function.